One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Rhonda M. Cooper‐DeHoff, Mikko Niemi, Laura B. Ramsey, Jasmine A. Luzum, E. Katriina Tarkiainen, Robert J. Straka, Li Gong, Sony Tuteja, Russell A. Wilke, Mia Wadelius and 11 more
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. CYP2C9 encodes a phase I drug metabolizing enzyme responsible for the oxidation of some statins. Genetic variation in each of these genes alters systemic exposure to statins (i.e., simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, lovastatin), which can increase the risk for SAMS. We summarize the literature supporting these associations and provide therapeutic recommendations for statins based on SLCO1B1, ABCG2, and CYP2C9 genotype with the goal of improving the overall safety, adherence, and effectiveness of statin therapy. This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and simvastatin-induced myopathy.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Cooper‐DeHoff, R. M., Niemi, M., Ramsey, L. B., Luzum, J. A., Tarkiainen, E. K., Straka, R. J., Gong, L., Tuteja, S., Wilke, R. A., Wadelius, M., Larson, E. A., Roden, D. M., Klein, T. E., Yee, S. W., Krauss, R. M., Turner, R. M., Palaniappan, L. P., Gaedigk, A., Giacomini, K. M., … Voora, D. (2022). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms. Clinical Pharmacology & Therapeutics, 111(5), 1007–1021. https://doi.org/10.1002/cpt.2557
Cooper‐DeHoff, Rhonda M., et al. "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms." Clinical Pharmacology & Therapeutics, vol. 111, no. 5, 2022, pp. 1007–1021, https://doi.org/10.1002/cpt.2557.
Cooper‐DeHoff, Rhonda M., Mikko Niemi, Laura B. Ramsey, Jasmine A. Luzum, E. Katriina Tarkiainen, Robert J. Straka, Li Gong, et al. "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms." Clinical Pharmacology & Therapeutics 111, no. 5 (2022): 1007–1021. https://doi.org/10.1002/cpt.2557.
Cooper‐DeHoff R. M., Niemi M., Ramsey L. B. [и др.] The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms // Clinical Pharmacology & Therapeutics. — 2022. — Vol. 111, № 5. — P. 1007–1021. — URL: https://doi.org/10.1002/cpt.2557
@article{cooperdehoff2022clinical,
title = {{The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms}},
author = {Rhonda M. Cooper‐DeHoff and Mikko Niemi and Laura B. Ramsey and Jasmine A. Luzum and E. Katriina Tarkiainen and Robert J. Straka and Li Gong and Sony Tuteja and Russell A. Wilke and Mia Wadelius and Eric A. Larson and Dan M. Roden and Teri E. Klein and Sook Wah Yee and Ronald M. Krauss and Richard Myles Turner and Latha P Palaniappan and Andrea Gaedigk and Kathleen M. Giacomini and Kelly E. Caudle and Deepak Voora},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2022},
volume = {111},
number = {5},
pages = {1007--1021},
doi = {10.1002/cpt.2557},
url = {https://doi.org/10.1002/cpt.2557}
}TY - JOUR AU - Cooper‐DeHoff, Rhonda M. AU - Niemi, Mikko AU - Ramsey, Laura B. AU - Luzum, Jasmine A. AU - Tarkiainen, E. Katriina AU - Straka, Robert J. AU - Gong, Li AU - Tuteja, Sony AU - Wilke, Russell A. AU - Wadelius, Mia AU - Larson, Eric A. AU - Roden, Dan M. AU - Klein, Teri E. AU - Yee, Sook Wah AU - Krauss, Ronald M. AU - Turner, Richard Myles AU - Palaniappan, Latha P AU - Gaedigk, Andrea AU - Giacomini, Kathleen M. AU - Caudle, Kelly E. AU - Voora, Deepak TI - The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms JO - Clinical Pharmacology & Therapeutics VL - 111 IS - 5 SP - 1007 EP - 1021 PY - 2022 DA - 2022/02/12 DO - 10.1002/cpt.2557 UR - https://doi.org/10.1002/cpt.2557 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.